• Shares of Amicus Therapeutics, Inc. (FOLD - Free Report) soared 25.9% following news that the company has received permission from the U.S. Food and Drug Administration to submit an experimental drug for approval
• Simulations Plus, Inc.’s (SLP - Free Report) shares gained 6.2% after posting fiscal third-quarter revenues of $6.75 million, outpacing the Zacks Consensus Estimate of $6 million
• Shares of Arena Pharmaceuticals, Inc. surged 41.4% following positive mid-stage trial results for its drug ralinepag
• Evogene Ltd’s (EVGN - Free Report) shares surged 10.8% after the company declared that it has reached an important stage in crop disease collaboration with Monsanto Company
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
• Shares of Amicus Therapeutics, Inc. (FOLD - Free Report) soared 25.9% following news that the company has received permission from the U.S. Food and Drug Administration to submit an experimental drug for approval
• Simulations Plus, Inc.’s (SLP - Free Report) shares gained 6.2% after posting fiscal third-quarter revenues of $6.75 million, outpacing the Zacks Consensus Estimate of $6 million
• Shares of Arena Pharmaceuticals, Inc. surged 41.4% following positive mid-stage trial results for its drug ralinepag
• Evogene Ltd’s (EVGN - Free Report) shares surged 10.8% after the company declared that it has reached an important stage in crop disease collaboration with Monsanto Company
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on SLP - FREE
Get the latest research report on FOLD - FREE
Get the latest research report on EVGN - FREE